Inventiva SA
PAR:IVA

Watchlist Manager
Inventiva SA Logo
Inventiva SA
PAR:IVA
Watchlist
Price: 2.945 EUR 0.68%
Market Cap: 443.2m EUR

EV/EBITDA
Enterprise Value to EBITDA

-4.4
Current
-5.1
Median
3.8
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-4.4
=
Enterprise Value
395.1m EUR
/
EBITDA
-90.8m EUR
Market Cap EV/EBITDA
FR
Inventiva SA
PAR:IVA
443.2m EUR -4.4
FR
Pharnext SCA
OTC:PNEXF
6T USD -201 247.5
US
Abbvie Inc
NYSE:ABBV
327.9B USD 15.1
US
Amgen Inc
NASDAQ:AMGN
152.5B USD 13.9
US
Gilead Sciences Inc
NASDAQ:GILD
138.3B USD 10.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.9B USD 24.7
US
Epizyme Inc
F:EPE
94.1B EUR -561.4
AU
CSL Ltd
ASX:CSL
120.8B AUD 17.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
65.5B USD 13.1
US
Seagen Inc
F:SGT
39.3B EUR -64.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
38.2B USD -632.4
EBITDA Growth EV/EBITDA to Growth
FR
Inventiva SA
PAR:IVA
Average EV/EBITDA: 15.7
Negative Multiple: -4.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 247.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.1
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
13.9
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.7
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.4 N/A N/A
AU
CSL Ltd
ASX:CSL
17.5
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.1
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -632.4 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-5.1
2-Years Forward
EV/EBITDA
-7.3
3-Years Forward
EV/EBITDA
-11.9